HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Phaarmasia Ltd Stock Comparison

Cohance Lifesciences Ltd vs Phaarmasia Ltd Stock Comparison

Last Updated on: May 27, 2025

Key Highlights

  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1092 as of 27 May 15:30.
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 yearsThe P/E Ratio of Phaarmasia Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 yearsThe Market Cap of Phaarmasia Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 322.86 crore as compare to the Sep '24 revenue of ₹ 271.84 crore. This represent the growth of 18.77% The revenue of Phaarmasia Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Suven Pharmaceuticals Ltd for the Dec '24 is ₹ 133.41 crore as compare to the Sep '24 ebitda of ₹ 118.13 crore. This represent the growth of 12.93% The ebitda of Phaarmasia Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 83.29 crore over 7 quarters. This represents a CAGR of -19.06% The net profit of Phaarmasia Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Phaarmasia Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

About Phaarmasia Ltd

  • Incorporated in 1981, Phaarmasia Limited (unit-I) is the part of the Maneesh Pharmaceutical Limited, with its headquarters and marketing office in Mumbai.
  • M/s Phaarmasia Limited Unit-II was established in 1993-94.
  • The Company is engaged in manufacturing and marketing of Oral contraceptive tablets' with various therapeutic dosage combinations along with iron tablets for Ministry of Health & Family Welfare and for Exports. The plant is situated in a hygienic environment; free from dust, smoke, chemical & biological emission.
  • Phaarmasia Ltd. Is an independent State-of-the-art-manufacturing unit having manufacturing facility of international standards with manufacturing capacity of more than 30 million units per annum. During the year 2000, the company became a Sick Industrial Company under SICA and therefore the same was referred to the BIFR.

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

Phaarmasia Ltd News Hub

News

Phaarmasia to convene board meeting

Phaarmasia will hold a meeting of the Board of Directors of the Company on 28 May 2025. Po...

Read more

24 May 2025 18:26

News

Phaarmasia to hold board meeting

Phaarmasia will hold a meeting of the Board of Directors of the Company on 14 February 202...

Read more

12 Feb 2025 11:01

News

Phaarmasia to hold board meeting

Phaarmasia will hold a meeting of the Board of Directors of the Company on 5 November 2024...

Read more

02 Nov 2024 13:46

News

Phaarmasia to discuss results

Phaarmasia will hold a meeting of the Board of Directors of the Company on 12 August 2024....

Read more

10 Aug 2024 12:48

News

Phaarmasia to announce Quarterly Result

Phaarmasia will hold a meeting of the Board of Directors of the Company on 25 May 2024 Pow...

Read more

18 May 2024 16:49

News

Phaarmasia to conduct board meeting

Phaarmasia will hold a meeting of the Board of Directors of the Company on 13 February 202...

Read more

06 Feb 2024 12:06

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Phaarmasia Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Suven Pharmaceuticals Ltd and Phaarmasia Ltd

Which company has a larger market capitalization, Suven Pharmaceuticals Ltd or Phaarmasia Ltd?

Market cap of Suven Pharmaceuticals Ltd is 27,815 Cr while Market cap of Phaarmasia Ltd is 19 Cr

What are the key factors driving the stock performance of Suven Pharmaceuticals Ltd and Phaarmasia Ltd?

The stock performance of Suven Pharmaceuticals Ltd and Phaarmasia Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Pharmaceuticals Ltd and Phaarmasia Ltd?

As of May 27, 2025, the Suven Pharmaceuticals Ltd stock price is INR ₹1092.65. On the other hand, Phaarmasia Ltd stock price is INR ₹28.78.

How do dividend payouts of Suven Pharmaceuticals Ltd and Phaarmasia Ltd compare?

To compare the dividend payouts of Suven Pharmaceuticals Ltd and Phaarmasia Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions